

PRESS RELEASE – FOR IMMEDIATE RELEASE

IntegraGen Reports First Half 2014 Financial Results

Clear improvement in profitability and cash

- Successful capital increase with a twice oversubscribed public offering completed in June 2014
- Reduced losses in first half 2014 compared to the first half of 2013
- Established the first European sequencing platform for clinical research use within Institut Gustave Roussy, one of the world’s leading cancer-research institutes and the biggest health center dedicated to oncology in Europe
- Launched Interpretation of Clinical Exome (ICE) project to develop software which will assist oncologists to interpret and utilize genomic data from cancer patients:
 - Obtained 2.5 million euro in funding from French Government for the ICE project
 - Project partners include Sogeti High Tech, Gustave Roussy and INSERM
- Presented data at ASCO 2014 demonstrating that the one of the company’s proprietary oncology biomarker is predictive of progression-free survival in patients with metastatic colon cancer
- Continued commercialization in the United-States of the ARISK® Test, a genetic test which predicts autism risk in children

EVRY, France, (October 7, 2014) - IntegraGen (FR0010908723 – ALINT – PEA SME Eligible), a leading player in genome analysis and the development and commercialization of molecular diagnostic tests in oncology and autism, announces today its results for the first half 2014 interim financial statements which were reviewed by the Board of Directors held September 16, 2014.

KEY INDICATORS (in thousand EUROS)	H1 2014 (6 Months)	H1 2013 (6 Months)	Var. %
Revenue	2,592	2,665	-3%
Operating result	- 997	- 1,629	+39%
Net result	- 746	-1,424	+48%

	30 June 2014	31 Dec. 2013	
Cash position – In thousand euros	5,850	2,834	+65%

Bernard Courtieu, President and CEO of IntegraGen, stated:

"IntegraGen strengthened during the first quarter of 2014 by advancing its structure for the future. First of all, we received considerable support from our shareholders, old and new, who strongly supported our capital increase in June allowing IntegraGen to have an adequate cash flow to enable us to implement our business development strategy. Then, our financial results were significantly improved with a reduced financial loss during first half of the year despite flat sales. This demonstrates our ability to manage operations and we expect revenue growth over the remainder of

the year supported by implementation of new genomic sequencing activities that will have a positive impact on our second half results. In parallel with the above, we are especially proud to have established our first sequencing unit to support clinical research activities and launch an innovative project, in conjunction with academic and private partners, designed to assist with the interpretation of genomic sequencing data to help guide physicians towards appropriate cancer therapies. Finally, our activities associated with the development of molecular diagnostic tools for cancer and autism renew our commercial goals for 2014 and 2015. With these financial and operational strengths, IntegraGen has the ability to deploy new genomic service offerings and market its molecular diagnostic products and personalized medicine solutions."

FINANCIAL DATA FOR INTEGRAGEN SA

▪ Income Statement

IntegraGen's **revenue** for the first half of 2014 was to €2.59 million compared to €2.66 million during the same period in 2013. This slight drop was a result of a cyclical downturn in sales during May. After accounting for operating subsidies, depreciation, amortization and provisions, revenues were €2.62 million versus €2.71 million during the first half of 2013, a decrease of 3%.

Operating expenses totaled €3.61 million; a decrease of 17% compared to the first half of 2013. This decrease primarily reflects the reduction of external costs associated with completion of several 2013 biomarker-related research projects that weighed more on the operational costs of the company.

The operating loss amounted to €1.00 million during in the first half of 2013 against a loss of €1.63 million in the first half of 2013, a reduction of 39%.

After taking into account the financial results, and an exceptional research tax credit related to the projects conducted during the period, net income was a loss of €0.75 million in the first six months of the year, against a loss of €1.42 million in the first half of 2013, a loss reduction of 48%.

▪ Balance Sheet

Net cash as of 30 June 2014 was €5.85 million compared to €2.83 million at end December, 2013. The Company completed a capital increase of €4.60 million in June 2014 with a public offering. Total cash outflow amounted to €1.10 million versus €2.00 million during the same period in 2013, a 45% reduction.

ACTIVITIES

▪ Genomic Services

Genomic services revenue remained virtually stable, down €70 thousand compared to H1 2013, during which time an 18% growth had been recorded. The use of IntegraGen's genomic services remains strong, especially for high-throughput sequencing. A new sequencing unit installed at Gustave Roussy became operational at the beginning of June 2014 with the first samples from clinical research studies analyzed by the end of this reporting period.

In conjunction with Gustave Roussy, INSERM and Sogeti High Tech (Cap Gemini), IntegraGen announced the launch of the "ICE" Project in June 2014. This software development program will support the interpretation of sequencing data and is partially funded by the FUI 17 (Single Interministerial Fund). This software will isolate, from tens of data gigabytes generated and associated with the genomic analysis of oncology patients, information which has clinical relevance and can impact the care of cancer patients. This will assist oncologists to select the most appropriate drug therapies and the creation of customized, tumor-specific, treatment protocols. This project is expected to result in a service offering to institutions and clinicians who

perform clinical sequencing for cancer patients in 2016. The ICE project is being funded by local authorities and BPI France in the amount of €2.5 million.

- **Oncology**

Validation studies associated with the company's proprietary oncology biomarker which measures treatment response in metastatic colon cancer patients were presented in May 2014 at the annual ASCO meeting in Chicago. These studies reported that by measuring the expression of the company's microRNA, IntegraGen enables the ability to predict treatment response to the latest generation of a class of therapeutic agents aimed at metastatic colorectal cancer. IntegraGen is developing a test based on these results which will permit physicians to personalized treatment approaches which avoid the use of unnecessary, and potentially harmful, drug therapies while also allowing for the early use of more effective therapeutic approaches.

- **Autism**

IntegraGen presented data on the ARISK2[®] Autism Risk Assessment Test during the International Meeting for Autism Research (IMFAR) in May 2014. This latest version of the ARISK[®] Test assesses the risk of autism spectrum disorder in young children with signs of developmental delay or autism, significantly expanding the market far beyond the original version of the test which was limited to children who had a sibling previously diagnosed with autism. The commercial development of ARISK[®] test continues in the United States.

OUTLOOK

Genomic Services revenue growth should be stronger in the second half of 2014, especially with the initial billing of onsite services the Company is offering at Gustave Roussy. The company also anticipates offering services associated with the installation and operation of similar clinical sequencing and RNA expression platforms in additional centers in 2014.

The company will continue to focus on molecular diagnostic-related commercialization associated activities in the field of oncology and autism during the remainder of 2014 into 2015. A primary focus will be the continued commercial development of these tests in conjunction with research partners with an objective to establish licensing and distribution agreements for these tests during the next twelve months.

The company also expects that the financial results during the second half of 2014 will be in line with those reported for the first half, including marked improvement in earnings and cash flow.

ABOUT INTEGRAGEN

IntegraGen is a company specialized in deciphering the human genome by performing genomic analyses for academic and private laboratories and developing diagnostic tools within the fields of oncology and autism. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. For autism, IntegraGen has developed the ARISK[®] Test, the first test marketed in the United States to assess the risk of autism spectrum disorder in children.

As of June 30 2014, IntegraGen had 34 employees and had generated revenue of €5.4 million in 2013 Based in the Evry Genopole, Integragen also has an office in the Cambridge, Massachusetts in the United States.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tél. : +33 (0)1 60 91 09 00

NEWCAP

Investor and Media Relations

Emmanuel HUYNH
Louis-Victor DELOUVRIER
Nicolas MERIGEAU
integragen@newcap.fr
Tél. : +33 (0)1 44 71 94 94

As of JUNE 30, 2014

Income Statement – IntegraGen SA			
<i>in K€</i>	30/06/2014	30/06/2013	Variance
Revenues	2,592,407	2,665,450	2,255,924
Other operating revenues	24,177	42,911	24,900
Total Revenues	2,616,584	2,708,361	2,280,824
Purchases and external charges	-2,114,687	-2,886,380	-2,255,096
Taxes	-47,879	-40,337	-45,835
Personnel expenses	-1,372,576	-1,287,890	-1,169,555
Depreciation, amortization, and provisions	-46,318	-46,392	-54,307
Other charges	-32,517	-76,775	-30,469
Total Operating Expenses	-3,613,977	-4,337,774	-3,555,262
Total Operating Income	-997,393	-1,629,413	-1,274,438
Finance income	50,567	68,390	124,407
Finance charges	-41,854	-100,595	-92,509
Total finance items	8,713	-32,205	31,898
Extraordinary income	1,304,003	4,670	19,440
Extraordinary charges	-1,278,800	-6,110	-49,889
Total extraordinary items	25,203	-1,440	-30,449
Income tax (CIR)	217,382	238,994	273,844
Net results	-746,095	-1,424,064	-999,145

BALANCE SHEET - INTEGRAGEN SA

ASSETS		
in euros	30/06/2014	30/06/2013
Intangible assets	5,699	
Tangible assets	228,170	188,832
Financial assets	333,667	430,111
Total current assets	567,536	618,943
Stock	227,133	382,870
Operating receivables	1,435,002	1,828,622
Other receivables	822,440	1,181,236
Cash	5,849,759	2,875,445
Subtotal	8,334,334	6,268,173
Total assets	8,901,870	6,887,116

LIABILITIES		
in euros	30/06/2014	30/06/2013
Share capital	4,967,322	4,115,471
Issue Premium	35,592,664	32,327,310
Reserves and retained earnings	-35,750,912	-33,205,292
Profit (loss)	-746,096	-1,424,064
Equity	4,062,978	1,813,425
Conditional advances	1,655,038	1,178,784
Provisions for risks and charges	3,557	4,096
Financial Debt	611	109
Payables	1,350,288	2,048,198
Other liabilities	1,829,398	1,842,504
Total debt	3,180,297	3,890,811
Total liabilities	8,901,870	6,887,116